Two key findings regarding the cardiovascular risks associated with obesity have emerged in recent years: one relates to the importance of visceral obesity as a risk factor for cardiovascular disease, and the other to the recognition that adipose tissue can be regarded as a large endocrine organ that directly contributes to cardiovascular risk by secreting a number of molecules known to modulate vascular, metabolic, inflammatory and other functional aspects of the cardiovascular system. Therefore, abdominal fat deposition, which is characterized by increase in waist circumference, should be the target of clinical intervention in obese individuals.
Introduction
Obesity is a key risk factor for the development of cardiovascular disease, second only to cigarette smoking. Even a modest increase in body weight (body mass index (BMI) 30 kg=m 2 ) results in a four-fold increase in the risk of cardiovascular disease in both men and women 1 ( Figure 1 ). In 1988, the American Heart Association reclassified obesity as a major, modifiable risk factor for coronary heart disease. 2 This represented a step forward from the earlier belief that obesity contributed to heart disease primarily through obesity-related covariates such as hypertension, dyslipidaemia and impaired glucose tolerance or type 2 diabetes.
In recent years, it has become increasingly clear that the distribution of adipose tissue is important when considering the risks of obesity. Cardiovascular and metabolic risk is more closely correlated to 'android' obesity (visceral obesity or upper body obesity) than to 'gynoid' obesity (lower body obesity). This was first suggested in 1947 by the French physician Jean Vague and was more recently shown in a number of studies. For example in the prospective Honolulu Heart study, 3 which followed almost 8000 men over 12 y (Figure 2 ), the risk of coronary artery disease was as high in the non-obese group with visceral obesity as it was in obese individuals with visceral obesity. In contrast, obese individuals with lower body obesity had a minimal increase in risk compared with non-obese individuals with lower body obesity. This shows the importance of focusing attention on visceral obesity, as it is this fat that contributes most to the development of cardiovascular disorders.
Visceral obesity refers to the accumulation of adipose tissue within the abdomen. Abdominal fat deposition is characterized by an increase in waist circumference, and this measurement is better than BMI as an indicator of cardiovascular and metabolic risk.
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Insulin-resistant adipocytes
There are both anatomical and metabolic differences between abdominal and subcutaneous adipose tissue. Intraabdominal adipose tissue is not only more metabolically active, 6 but also contains large insulin-resistant adipocytes while adipose tissue associated with lower body obesity contains small, insulin-sensitive adipocytes. 7 The adrenergic control of adipose tissue also differs in that the large adipocytes found in abdominal adipose tissue have a higher density of adrenergic receptors than the small cells in lower body obesity.
The combination of decrease in insulin-mediated antilipolysis and increase in catecholamine-mediated lipolysis in abdominal adipose tissue results in increased circulating levels of non-esterified fatty acids in plasma. This has been shown in metabolic studies in which plasma concentration of free fatty acids, plasma free fatty acid turnover rate and hepatic glucose production were all higher in individuals with abdominal obesity than those with lower body obesity or controls.
These metabolic aspects of abdominal adipose tissue are not the only contributors to cardiovascular risk. Visceral obesity is also associated with hypertension, renal hyperfiltration, increased inflammatory response, increase in prothrombotic factors, endothelial dysfunction and several lipid abnormalities ( Figure 3 ). All of these factors can contribute to the development of cardiovascular disease and end-organ damage in obese patients.
Adipose tissue as an endocrine organ
Until recently, the adipocyte was largely thought to be an inert storage cell whose main function was to store excess energy in the form of triglycerides. It is now apparent that adipocytes have a more complex role in the organism. Thus, adipocytes produce a large number of hormones, peptides and smaller molecules that impact on metabolism and on cardiovascular regulation, not only in an autocrine and paracrine manner but also in an endocrine manner. This supports the view that adipose tissue must be regarded as an endocrine organ. 9 One of the key vasoactive substances produced by adipocytes is leptin, which is an important regulator of food intake. Leptin acts at the level of the hypothalamus and down-regulates neuropeptide Y, leading to decreased hunger, increased activity and increased thermogenesis. It is also associated with an increase in sympathetic activity. 10 Infusion of leptin into the carotid artery of dogs results in a dose-dependent increase in both arterial pressure and heart rate.
11
There are also a number of studies in man showing good correlation between plasma leptin levels and heart rate. 12 Hence, leptin derived from adipose tissue drives sympathetic activity, which in turn contributes not only to volume retention (one of the hallmarks of obesity), but also to an increase in heart rate, resulting in the increase in cardiac output and blood pressure characteristic of obesity. Figure 4 summarizes the central effects of leptin.
The adipocyte also appears to express all components of the renin-angiotensin system, 13 and this system is now believed to play an important role in the differentiation of the adipocyte. 14 In recent biopsy studies, we have demonstrated a correlation between 24 h blood pressure and the expression of genes related to the renin -angiotensin system (angiotensin converting enzyme and angiotensin type 1 receptor genes) in human adipocytes. 15 This suggests that the renin -angiotensin system of adipose tissue might be involved in the aetiology of obesity-related hypertension.
Other adipocyte-derived molecules, including prostaglandins, adiponectin 16 and the more recently discovered molecule resistin, 17 affect metabolic function and might have a Adipose tissue AM Sharma role in the regulation of cardiovascular end organ damage. Thus, leptin has been shown to enhance calcification of vascular smooth muscle cells. 18 We have also recently demonstrated that perivascular adipose tissue releases a factor that significantly modulates vascular response to constrictive stimuli. 19 In addition, obese individuals have high circulating plasma levels of a range of inflammatory markers and thrombogenic factors produced by adipose tissue including TNF-alpha, 20 interleukin-1 and fibrinogen. These factors, which can be reduced by weight loss, are likely to contribute to vascular damage in obese individuals.
Thus, the picture that is emerging is that adipose tissue itself is the source of many of the metabolic and cardiovascular abnormalities that determine the increased cardiovascular risk associated with obesity.
Conclusion
Abdominal adipose tissue carries the greatest metabolic and cardiovascular risk for patients and it is clear that we need to target abdominal obesity in treating obese patients. Even a modest weight reduction of 5 -10% can lead to marked reductions in blood pressure, susceptibility to thrombosis, and inflammatory markers and to a marked improvement in the lipid profile and insulin sensitivity, as shown in Figure 5 . 21 
